Skip to main content

Advertisement

SpringerLink
Log in

Novel Interventions for the Prevention of Preeclampsia

  • Preeclampsia (VD Garovic, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review the rationale and biological plausibility and discuss the current research on novel interventions for the prevention of preeclampsia.

Recent Findings

Preeclampsia affects up to 8% of pregnancies worldwide and remains a major cause of maternal and neonatal morbidity and mortality. Multiple medications have been investigated or repurposed as potential effective interventions for preeclampsia prevention. Aspirin is currently the only drug for which there is some evidence of benefit for preeclampsia prevention, and its use is recommended by professional societies for pregnancies at risk. Statins have shown promise for prevention of preeclampsia in animal models and human pilot studies, without any trend or concerns for safety signals or teratogenicity. The use of metformin has also gained popularity in experimental studies, but observations from randomized clinical trials were not consistent on its utility as a possible intervention for preeclampsia prevention. While initial studies evaluating esomeprazole were promising, randomized trials failed to show benefit.

Summary

Contemporary research shows exciting new opportunities for prophylactic treatment for preeclampsia, to prevent this debilitating and life-threatening disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631–44.

    Article  PubMed  Google Scholar 

  2. • Espinoza J, Vidaeff A, Pettker CM, Simhan H. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):e1–25.

    Article  Google Scholar 

  3. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31.

    Article  Google Scholar 

  4. Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–200.

    Article  PubMed  Google Scholar 

  5. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–74.

    Article  PubMed  Google Scholar 

  6. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–7.

    Article  PubMed  Google Scholar 

  7. MacKay AP, Berg CJ, Duran C, Chang J, Rosenberg H. An assessment of pregnancy-related mortality in the United States. Paediatr Perinat Epidemiol. 2005;19:206–14.

    Article  PubMed  Google Scholar 

  8. Cunningham F, Leveno K, Bloom F, Spong C, Dashe J, Hoffman B. Williams obstetrics. 24th ed. New York: McGraw-Hill Education; 2014.

    Google Scholar 

  9. Esplin M, Fausett M, Fraser A, Kerber R, Mineau G, Carrillo J, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2011;344(12):867–72.

    Article  Google Scholar 

  10. World Health Organization. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 1988;158(1):80–3.

    Article  Google Scholar 

  11. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30(Suppl A):S32–7.

    Article  PubMed  CAS  Google Scholar 

  12. Costantine MM, Ananth CV. The early developments of preeclampsia drugs. Expert Opin Investig Drugs. 2016;25(8):867–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. • Sargent IL, Germain SJ, Sacks GP, Kumar S, Redman CWG. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J Reprod Immunol. 2003;59:153–60.

    Article  CAS  PubMed  Google Scholar 

  14. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998;179:1359–75.

    Article  CAS  PubMed  Google Scholar 

  15. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22.

    Article  CAS  PubMed  Google Scholar 

  16. Roberts JM. Pathophysiology of ischemic placental disease. Semin Perinatol. 2014;38(3):139–45.

    Article  PubMed  Google Scholar 

  17. Herraiz I, Llurba E, Verlohren S, Galindo A, Bartha JL, De La Calle M, et al. Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/PlGF ratio in singleton pregnancies. Fetal Diagn Ther. 2018;43(2):81–9.

    Article  PubMed  Google Scholar 

  18. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.

    Article  CAS  PubMed  Google Scholar 

  19. Venkatesha S, Toporsian M, Lam C, Hanai JI, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.

    Article  CAS  PubMed  Google Scholar 

  20. Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, Kim MR, et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med 2005;18(1):9–16.

  21. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Gonçalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: young investigator award. Am J Obstet Gynecol. 2004;190:1541–50.

    Article  CAS  PubMed  Google Scholar 

  22. • Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;11(5):649–58.

    Article  Google Scholar 

  23. Szalai G, Romero R, Chaiworapongsa T, Xu Y, Wang B, Ahn H, et al. Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One. 2015;10(4):e0119547.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fat Acids. 2004;70:223–32.

    Article  CAS  Google Scholar 

  25. Walsh SW. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol. 1985;152(3):335–40.

    Article  CAS  PubMed  Google Scholar 

  26. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300:1142–7.

    Article  CAS  PubMed  Google Scholar 

  27. Mills JL, DerSimonian R, Raymond E, Morrow JD, Roberts LJ, Clemens JD, et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. J Am Med Assoc. 1999;282(4):356–62.

    Article  CAS  Google Scholar 

  28. • Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132(1):e44–52.

    Article  Google Scholar 

  29. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for prevention of preeclampsia. Drugs. 2017;77:1819–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev. 2012;64(3):540–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Paul BZS, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A2-induced platelet aggregation. J Biol Chem. 1999;274(41):29108–14.

    Article  CAS  PubMed  Google Scholar 

  32. Patrick J, Dillaha L, Armas D, Sessa WC. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad Med. 2015;127:573–80.

    Article  PubMed  Google Scholar 

  33. Lin L, Li G, Zhang W, Wang Y, Yang H. Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK/AP-1 pathway in human trophoblast and endothelial cells. J Cell Physiol. 2019;234(10):18928–41.

    Article  CAS  PubMed  Google Scholar 

  34. Li C, Raikwar NS, Santillan MK, Santillan DA, Thomas CP. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. Placenta. 2015;36(4):446–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Crandon AJ, Isherwood DM. Effect of aspirin on incidence of preeclampsia. Lancet. 1979;1:1356.

    Article  CAS  PubMed  Google Scholar 

  36. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med. 1998;338(11):701–5.

    Article  CAS  PubMed  Google Scholar 

  37. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet. 1994;343(8898):619–29.

    Article  Google Scholar 

  38. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med. 1993;329(17):1213–8.

    Article  CAS  PubMed  Google Scholar 

  39. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018;218(3):287–93 e1.

    Article  CAS  PubMed  Google Scholar 

  40. • LeFevre ML. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(11):819–26.

    Article  PubMed  Google Scholar 

  41. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol. 2017;216(2):121–8 e2.

    Article  CAS  PubMed  Google Scholar 

  42. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110–20 e6.

    Article  CAS  PubMed  Google Scholar 

  43. Rolnik DL, Wright D, Poon LCY, Syngelaki A, O’Gorman N, de Paco MC, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50:492–5.

    Article  CAS  PubMed  Google Scholar 

  44. Rolnik DL, O’Gorman N, Roberge S, Bujold E, Hyett J, Uzan S, et al. Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation. Ultrasound Obstet Gynecol. 2017;50:551–6.

    Article  CAS  PubMed  Google Scholar 

  45. Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015;46:419–23.

    Article  CAS  PubMed  Google Scholar 

  46. Poon LCY, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812–8.

    Article  CAS  PubMed  Google Scholar 

  47. Rolnik DL, Wright D, Poon L, O’Gorman N, Syngelaki A, Matallana C. de P, et al. aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. N Engl J Med. 2017;377(7):613–22.

    Article  CAS  PubMed  Google Scholar 

  48. Ayala NK, Rouse DJ. A nudge toward universal aspirin for preeclampsia prevention. Obstet Gynecol. 2019;133(4):725–8.

    Article  PubMed  Google Scholar 

  49. Mone F, Mulcahy C, McParland P, McAuliffe FM. Should we recommend universal aspirin for all pregnant women? Am J Obstet Gynecol. 2017;216(2):141.e1–5.

    Article  Google Scholar 

  50. Werner EF, Hauspurg AK, Rouse DJ. A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol. 2015;126(6):1242–50.

    Article  CAS  PubMed  Google Scholar 

  51. Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2014;160:695–703.

    Article  PubMed  Google Scholar 

  52. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon H. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). Reg Anesth Pain Med. 2018;43:263–309.

    Article  PubMed  Google Scholar 

  53. Sibai BM, Mirro R, Chesney C, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol. 1989;74(4):551–7.

    CAS  PubMed  Google Scholar 

  54. •• Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. PARIS Collaborative Group. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791–8 Individual patient data metaanalysis evaluating the benefit of antiplateelt agents, especially aspirin for the prevention of preeclmapsia and other pregnancy outcomes.

    Article  CAS  PubMed  Google Scholar 

  55. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;2:CD004659.

    Google Scholar 

  56. Caniggia I, Post M, Ermini L. Statins, mevalonate pathway and its intermediate products in placental development and preeclampsia. Curr Mol Pharmacol. 2016;10:152–60.

    Article  CAS  Google Scholar 

  57. •• Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci. 2010;108(4):1451–5 The authors tested pravastatin ability to reverse various features of preeclampsia using a novel mouse model.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Kaitu’u-Lino TJ. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth. 2016;16:117.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GDV, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010;116(116):114–20.

    Article  CAS  PubMed  Google Scholar 

  60. Saad AF, Kechichian T, Yin H, Sbrana E, Longo M, Wen M, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci. 2014;21:138–45.

    Article  PubMed  CAS  Google Scholar 

  61. Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. J Reprod Immunol. 2017;124:15–20.

    Article  CAS  PubMed  Google Scholar 

  62. Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, Regal JF, et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension. 2013;61:1103–10.

    Article  CAS  PubMed  Google Scholar 

  63. Fox KA, Longo M, Tamayo E, Kechichian T, Bytautiene E, Hankins GDV, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011;205(4):366.e1–5.

    Article  CAS  Google Scholar 

  64. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58(4):716–24.

    Article  CAS  PubMed  Google Scholar 

  65. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet Gynecol Surv. 2018;73(1):40–55.

    Article  PubMed  Google Scholar 

  66. Garrett N, Pombo J, Umpierrez M, Clark JE, Simmons M, Girardi G. Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice. JCI Insight. 2018;3(8):e120147.

    Article  PubMed Central  Google Scholar 

  67. Lefkou E, Mamopoulos A, Fragakis N, Dagklis T, Vosnakis C, Nounopoulos E, et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension. 2014;63:e118–9.

    Article  CAS  PubMed  Google Scholar 

  68. •• Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126(8):2933–40 This paper shows benefit of pravastatin in a prospective cohort of women with anti-phospholipid syndrome and adverse pregnancy outcomes.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66:687–97.

    Article  CAS  PubMed  Google Scholar 

  70. •• Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(720):e1–17 This paper reports the results of a pilot clinical trial using pravastatin to prevent preeclampsia in high-risk women. In addition to clinical outcomes, the authors looked at safety and pharmacokinetic parameters of pravastatin use in pregnancy.

    Google Scholar 

  71. Akbar M. Indonesia Pravastatin to Prevent Preeclampsia Study (INOVASIA), ClinicalTrials.gov Identifier: NCT03648970 [Internet]. ClinicalTrials.gov. 2018 [cited 2019 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03648970

  72. Costantine MM. Pravastatin for Prevention of Preeclampsia (Statin), ClinicalTrials.gov Identifier: NCT01717586 [Internet]. ClinicalTrials.gov. 2012 [cited 2019 Apr 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01717586

  73. Nicolaides KH. Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Preeclampsia [Internet]. ClinicalTrialsRegister.eu. 2016 [cited 2019 Apr 26]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-005206-19/GB

  74. Downey A. A Proof of Principle, Double-Blind, Randomised Placebo-Controlled,Multi-centre Trial of pravaStatin to Ameliorate Early Onset Pre-eclampsia, EudraCT number 2009–012968-13 [Internet]. ClinicalTrialsRegister.eu. 2011 [cited 2019 Apr 26]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012968-13/results

  75. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. J Clin Lipidol. 2016;10(5):1081–90.

    Article  PubMed  Google Scholar 

  77. Costantine MM, Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013;121:349–53.

    Article  CAS  PubMed  Google Scholar 

  78. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000;39:397–412.

    Article  CAS  PubMed  Google Scholar 

  79. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GDV, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013;209:373.e1–5.

    Article  CAS  Google Scholar 

  80. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–66.

    Article  CAS  PubMed  Google Scholar 

  81. Genest DS, Falcao S, Gutkowska J, Lavoie JL. Impact of exercise training on preeclampsia: potential preventive mechanisms. Hypertension. 2012;60:1104–9.

    Article  CAS  PubMed  Google Scholar 

  82. Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:356.e1–15.

    Article  CAS  Google Scholar 

  83. •• Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med. 2018;35:160–72.

    Article  CAS  PubMed  Google Scholar 

  84. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med 2016;374:434–43.

  85. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism. 2013;62(11):1522–34.

    Article  CAS  PubMed  Google Scholar 

  86. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358:2003–15.

    Article  CAS  PubMed  Google Scholar 

  87. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59:426–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. • Nanovskaya TN, Nekhayeva IA, Patrikeeva SL, Hankins GDV, Ahmed MS. Transfer of metformin across the dually perfused human placental lobule. Am J Obstet Gynecol. 2006;195:1081–5.

    Article  CAS  PubMed  Google Scholar 

  89. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83:1575–8.

    Article  PubMed  Google Scholar 

  90. Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:656–9.

    Article  CAS  PubMed  Google Scholar 

  91. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol. 2011;25:51–63.

    Article  PubMed  Google Scholar 

  92. Wouldes TA, Battin M, Coat S, Rush EC, Hague WM, Rowan JA. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed. 2016;101:F488–93.

    Article  PubMed  Google Scholar 

  93. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU) - body composition at 2 years of age. Diabetes Care. 2011;34:2279–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Rowan JA, Rush EC, Plank LD, Lu J, Obolonkin V, Coat S, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care. 2018;6(1):e000456.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Teng M, Khoo AL, Zhao YJ, Lin L, Lim BP, Wu TS, et al. Meta-analysis of the effectiveness of esomeprazole in gastroesophageal reflux disease and helicobacter pylori infection. J Clin Pharm Ther. 2015;40(4):368–75.

    Article  CAS  PubMed  Google Scholar 

  96. Saleh L, Samantar R, Garrelds IM, Van Den Meiracker AH, Visser W, Danser AHJ. Low soluble Fms-like tyrosine Kinase-1, endoglin, and endothelin-1 levels in women with confirmed or suspected preeclampsia using proton pump inhibitors. Hypertension. 2017;70(3):594–600.

    Article  CAS  PubMed  Google Scholar 

  97. Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69(3):457–68.

    Article  CAS  PubMed  Google Scholar 

  98. Kaitu’u-Lino TJ, Brownfoot FC, Beard S, Cannon P, Hastie R, Nguyen TV, et al. Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia. PLoS One. 2018;13(2):e0188845.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Cluver CA, Hannan NJ, van Papendorp E, Hiscock R, Beard S, Mol BW, et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am J Obstet Gynecol. 2018;219:388.e1–17.

    Article  CAS  Google Scholar 

  100. Schoenfeld AJ, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med. 2016;176(2):172–4.

    Article  PubMed  Google Scholar 

  101. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363:2114–23.

    Article  CAS  PubMed  Google Scholar 

  102. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009;104(6):1541–5.

    Article  CAS  PubMed  Google Scholar 

  103. Ornaghi S, Paidas MJ. Novel therapy for the treatment of early-onset preeclampsia. Clin Obstet Gynecol. 2017;60(1):169–82.

    Article  PubMed  Google Scholar 

  104. • Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health 2018;2(2):93–102.

  105. Levin G, Rottenstreich A. Sildenafil citrate in obstetrics—caution is advised. BJOG. 2019;126(6):736

  106. Turanov AA, Lo A, Hassler MR, Makris A, Ashar-Patel A, Alterman JF, et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol. 2018;36:1164–73.

    Article  CAS  Google Scholar 

  107. Robertson SA. Preventing preeclampsia by silencing soluble Flt-1? N Engl J Med. 2019;380:1080–2.

    Article  PubMed  Google Scholar 

Download references

Funding

This work is supported in part by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (5UG1HD027915–29 and 2 U54-HD047891–14) and the National Heart, Lung, and Blood Institute (1UG3HL140131–01). The manuscript does not necessarily represent the official views of the NICHD, NHLBI, or the National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Maternal Fetal Medicine, Department of Obstetrics & Gynecology, The Ohio State University College of Medicine, 395 W 12th Avenue, Columbus, OH, 43210, USA

    Marwan Ma’ayeh, Kara M. Rood, Douglas Kniss & Maged M. Costantine

Authors
  1. Marwan Ma’ayeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kara M. Rood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Kniss
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maged M. Costantine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marwan Ma’ayeh.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Preeclampsia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma’ayeh, M., Rood, K.M., Kniss, D. et al. Novel Interventions for the Prevention of Preeclampsia. Curr Hypertens Rep 22, 17 (2020). https://doi.org/10.1007/s11906-020-1026-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-020-1026-8

Keywords

Search

Navigation